Abstracts tagged "rheumatoid arthritis (RA) and tocilizumab"

Abstract Number: 2505 • 2012 ACR/ARHP Annual Meeting
Involvment of CD4⁺ FoxP3⁺ Regulatory T Cells in Interleukin-6 Receptor Targeted Treatment in Murine Arthritis and Rheumatoid Arthritis
Allan Thiolat¹, Jerome Biton¹, Luca Semerano¹, Yves-Marie Pers², Pierre Portales², Delphine Lemeiter¹, Patrice Decker¹, Christian Jorgensen², Pascale Louis-Plence², Natacha Bessis³ and Marie-Christophe Boissier⁴, ¹EA4222, Li2P, University Paris 13, Sorbonne Paris Cité and Rheumatology Department, Avicenne Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Bobigny, 93009, France, Bobigny, France, ²Department of therapy & Immuno-Rhumatology, Inserm U844, CHU saint-Eloi, Université Montpellier 1, CHU Lapeyronie, Montpellier, France, ³INSERM UMR 1125, Li2P, University Paris 13, Sorbonne Paris Cité and Rheumatology Department, Avicenne Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Bobigny, France, ⁴INSERM UMR 1125, Li2P, University Paris 13, Sorbonne Paris Cité, Bobigny, France
Background/Purpose: Studies have demonstrated the clinical efficacy of tocilizumab, a humanized anti-IL-6 receptor (R) antibody (Ab), in patients with rheumatoid arthritis (RA). The rational for…
Abstract Number: L8 • 2012 ACR/ARHP Annual Meeting
A Randomized, Double-Blind, Parallel-Group Study of the Safety and Efficacy of Tocilizumab Subcutaneous Versus Placebo in Combination with Traditional Dmards in Patients with Moderate to Severe Rheumatoid Arthritis (BREVACTA)
Alan J. Kivitz¹, Ewa Olech², Michael A. Borofsky³, Beatriz M. Zazueta⁴, Federico Navarro-Sarabia⁵, Lucy Rowell⁶, Clare Nasmyth-Miller⁶ and Janet E. Pope⁷, ¹Altoona Center for Clinical Research, Duncansville, PA, ²Internal Medicine, University of Nevada School of Medicine, Las Vegas, NV, ³Clinical Research Center of Reading, Reading, PA, ⁴Reumatologia, Centro de Investigacion en Enfermedades Reumaticas, Mexicali, Mexico, ⁵Rheumatology, University Hospital Virgen Macarena, Sevilla, Spain, ⁶Roche, Welwyn Garden City, United Kingdom, ⁷Medicine/Rheumatology, St. Joseph Health Care London, University of Western Ontario, London, ON, Canada
Background/Purpose: The intravenous formulation of tocilizumab (TCZ) has demonstrated efficacy with a manageable safety profile in patients (pts) with rheumatoid arthritis (RA) in multiple clinical…
Abstract Number: 2166 • 2012 ACR/ARHP Annual Meeting
Identification of Serological Biomarker Profiles Associated with Response to IL-6 Intervention in Rheumatoid Arthritis
Morten Asser Karsdal¹, Anne C. Bay-Jensen², Inger Byrjalsen³, Andrew Kenwright⁴, Adam Platt⁴, Thierry Sornasse⁵ and Claus Christiansen⁶, ¹Nordic Bioscience A/S, Herlev, Denmark, ²Cartilage Biomarkers and Research, Nordic Bioscience, Herlev, Denmark, ³Research & Development, Nordic Bioscience, Herlev, Denmark, ⁴Roche, Welwyn Garden City, United Kingdom, ⁵Product Development Immunology, Genentech, Inc., South San Francisco, USA, San Fransisco, CA, ⁶CCBR, Ballerup, Denmark
Background/Purpose: RA is characterized by poly-articular synovial inflammation, cartilage loss and erosion of subchondral bone. It is critical to diagnose and effectively treat the disease…
Abstract Number: 2167 • 2012 ACR/ARHP Annual Meeting
Serum Based Biomarkers of Joint Destruction Can Identify Responders and Non-Responder to Tocilizumab
Anne C. Bay-Jensen¹, Inger Byrjalsen², Claus Christiansen³ and Morten Asser Karsdal⁴, ¹Cartilage Biomarkers and Research, Nordic Bioscience, Herlev, Denmark, ²Research & Development, Nordic Bioscience, Herlev, Denmark, ³CCBR, Ballerup, Denmark, ⁴Nordic Bioscience A/S, Herlev, Denmark
Background/Purpose: RA is characterized by synovial inflammation, cartilage loss and erosion of subchondral bone. It is critical to diagnose and effectively treat the disease early…
Abstract Number: 2156 • 2012 ACR/ARHP Annual Meeting
Anti-Cyclic Citrullinated Protein Antibodies As a Predictor of Response to Tocilizumab in Patients with Rheumatoid arthritis A Prospective Study
Kensuke Kume¹, Kanzo Amano¹, Susumu Yamada¹, Kuniki Amano², Kazuhiko Hatta³, Hiroyuki Ohta⁴ and Noriko Kuwaba⁵, ¹Rheumatology, Hiroshima Clinic, Hiroshima, Japan, ²Rheumatology, Sky Clinic, Hiroshima, Japan, ³Rheumatology, Hatta Clinic, Kure, Japan, ⁴Medical Research, hiroshima clinic, Hiroshima, Japan, ⁵Medical Research, Sanki Clinical Link, Hiroshima, Japan
Background/Purpose: Tocilizumab, interleukin-6 receptor antibody is very effective in patients with rheumatoid arthritis (RA). Anti-cyclic citrullinated protein antibodies (ACPA) are highly specific and sensitive for…
Abstract Number: 2121 • 2012 ACR/ARHP Annual Meeting
A Multi-Biomarker Disease Activity (VECTRA™ DA Algorithm) Score Reflects Clinical Disease Activity and Structural Changes in Rheumatoid Arthritis Patients Treated with Tocilizumab
Yoshiya Tanaka¹, Kentaro Hanami², Hisashi Tasaka¹, Shunsuke Fukuyo¹, Douglas J. Haney³, Nadine Defranoux³, Rebecca Bolce³, Guy Cavet³, David Chernoff³, Kunihiro Yamaoka¹, Kazuyoshi Saito¹ and Shintaro Hirata¹, ¹The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ²The First Department of Internal Medicinei, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ³Crescendo Bioscience Inc., South San Francisco, CA
Background/Purpose: The multi-biomarker disease activity (MBDA) score assessed with 0.2 mL serum has been reported as a novel composite disease activity index for patients with…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].